#USA #Jersey City #Private Placement #WallachBeth Capital #Tenon Medical

WallachBeth Capital Announces Tenon Medical Pricing

On August 27, 2026, WallachBeth Capital LLC revealed that it has entered into a strategic agreement with Tenon Medical, Inc. This partnership involves Tenon Medical, a noted name on the Nasdaq (TNON), dedicated to revolutionizing treatment for sacro-pelvic disorders. The announcement highlights the sale of 597,610 shares of common stock and additional pre-funded warrants, along with warrants that give rights to purchase up to 1,058,517 shares of common stock.

The offering reflects a combined gross proceeds estimate approaching $3.0 million, before accounting for agent fees and related expenses. The effective pricing for each share of common stock, along with its associated warrants, has been set at $5.02, while the pre-funded warrants will have an access price of just $0.001. These warrants hold a lifespan of five years from the issuance date, with the objective of providing immediate execution availability to investors.

The closing date for this private placement is expected to be around August 31, 2026, provided all customary closing conditions are met. WallachBeth Capital is serving as the sole placement agent for this offering, aligned with its mission to connect healthcare innovators with vital capital resources.

It's important to note that this placement falls under Section 4(a)(2) of the Securities Act of 1933 and is conducted without undergoing the lengthy registration process that usually applies. Hence, shares sold under this offering won't be available for resale in the U.S. unless a proper registration statement is active.

Tenon Medical is focused on addressing significant healthcare needs related to sacro-pelvic disorders, and this financing is crucial for its objectives, including potential product development and market expansion. The funds garnered through this offering will likely support these operational visions.

Important Considerations

The agreement involves customary registration rights per the terms set in the purchase agreement, ensuring that Tenon Medical will work towards registering these securities in compliance with the Securities Act.

This news pertains to the broader context of investment dynamics in the medical device sector, where firms like Tenon are increasingly attracting financing through innovative means. WallachBeth Capital's involvement signifies a strengthened pathway for such medical advancements, supporting companies focused on significant health challenges.

WallachBeth Capital prides itself on its comprehensive financial and consulting services tailored for the healthcare sector, facilitating connections that lead to innovative solutions. Their expertise encompasses various facets of capital markets, including public offerings, PIPE dealings, and private transactions — crucial transactions that continue bolstering the healthcare industry.

Forward-Looking Statements

As with all leveraged financial agreements, uncertain elements surround future outcomes. Tenon Medical has highlighted the forward-looking nature of statements involving their anticipated progression and use of the proceeds from this offering. Factors affecting these expectations are influenced by market conditions and operational success. For ongoing updates, stakeholders are encouraged to monitor Tenon Medical's filings with the SEC, particularly focusing on updates regarding risk factors.

In conclusion, WallachBeth Capital’s announcement vividly illustrates the evolving landscape of medical investments, implying robust growth potential for Tenon Medical as it looks to innovate and expand its offerings in the healthcare market.